Evonik Half-Year Report 2024

 In a difficult environment, Evonik has delivered another strong quarter, exceeding analysts’ expectations. The company is therefore publishing preliminary key figures for the second quarter in advance and is materially raising its outlook for the fiscal year 2024.

As there was still no broad-based macroeconomic recovery, company-specific factors in particular led to this positive development: In addition to continued strict cost discipline, good volume development in Specialty Additives as well as a price recovery in Animal Nutrition and lower production costs were drivers of the sequential increase.

Highlights

• Adjusted EBITDA in second quarter well above prior year
• Further improvement also compared to already good first quarter
• Outlook for full year: Adjusted EBITDA expected between €1.9 billion and €2.2 billion